利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

32 条记录 (耗时 0.023 秒)

    REDUCED COLONIZATION OF MICROBES AT THE MUCOSA
    1.
    发明公开
    REDUCED COLONIZATION OF MICROBES AT THE MUCOSA 审中-公开

    公开(公告)号：EP3933029A3

    公开(公告)日：2022-03-23

    申请号：EP21169279.3

    申请日：2009-09-29

    申请人： Intrexon Actobiotics NV

    发明人： STEIDLER, Lothar

    IPC分类号： C12N1/00

    摘要： The invention is in the field of use of engineered microbes for the delivery and administration of therapeutic peptides or proteins to humans or animals suffering from a disease, or the use of engineered microbes for the delivery of antigens such as for vaccination purposes. More in particular, the invention relates to a recombinant microbe that has reduced capacity of colonizing the mucosa in comparison to its wild type ancestor, in particular when residing in the alimentary tract as part of a treatment or vaccination of a human or animal. In particular, the recombinant microbe contains an inactive thymidylate synthase gene that causes the reduced capability for the microbe to colonize in the alimentary tract. The invention also covers the use of said recombinant microbes comprising nucleic acids or vectors for expressing heterologous or homologous proteins; and also for delivery, especially therapeutic delivery, of the said proteins to animals or humans.

    REDUCED COLONIZATION OF MICROBES AT THE MUCOSA
    4.
    发明授权
    REDUCED COLONIZATION OF MICROBES AT THE MUCOSA 有权
    减量MIKROBENKOLONISIERUNG AT THE粘膜

    公开(公告)号：EP2344626B1

    公开(公告)日：2017-03-29

    申请号：EP09736880.7

    申请日：2009-09-29

    申请人： Intrexon Actobiotics NV

    发明人： STEIDLER, Lothar

    IPC分类号： C12N1/00

    CPC分类号： C12N1/36 ,  A61K47/6901 ,  A61K2039/523 ,  A61K2039/542 ,  A61K2039/55594 ,  C12N9/1007 ,  C12P21/02 ,  C12Y201/01045

    摘要： The invention is in the field of use of engineered microbes for the delivery and administration of therapeutic peptides or proteins to humans or animals suffering from a disease, or the use of engineered microbes for the delivery of antigens such as for vaccination purposes. More in particular, the invention relates to a recombinant microbe that has reduced capacity of colonizing the mucosa in comparison to its wild type ancestor, in particular when residing in the alimentary tract as part of a treatment or vaccination of a human or animal. In particular, the recombinant microbe contains an inactive thymidylate synthase gene that causes the reduced capability for the microbe to colonize in the alimentary tract. The invention also covers the use of said recombinant microbes comprising nucleic acids or vectors for expressing heterologous or homologous proteins; and also for delivery, especially therapeutic delivery, of the said proteins to animals or humans.

    LACTOBACILLUS AND STREPTOCOCCUS PROMOTERS AND USES THEREOF
    6.
    发明公开
    LACTOBACILLUS AND STREPTOCOCCUS PROMOTERS AND USES THEREOF 审中-公开
    乳杆菌和链球菌启动子及其用途

    公开(公告)号：EP3192873A1

    公开(公告)日：2017-07-19

    申请号：EP17159348.6

    申请日：2010-09-27

    申请人： Intrexon Actobiotics NV

    发明人： Steidler, Lothar ,  Van Huynegem, Karolien

    IPC分类号： C12N15/74 ,  C12R1/225 ,  C12R1/46 ,  C12N5/10

    CPC分类号： C07K14/335 ,  C07K14/315 ,  C12N9/0008 ,  C12N9/90 ,  C12N15/746 ,  C12P21/02

    摘要： The invention is in the field of molecular biology, and relates to recombinant engineering and protein expression. More in particular, the invention relates to nucleic acids for recombinant expression of proteins comprising sequences derived from Lactobacillus or Streptococcus and useful as promoters. The invention further relates to vectors comprising the said nucleic acids and host cells transformed therewith. The invention also covers the use of host cells comprising the said nucleic acids or vectors for expressing heterologous or homologous proteins; and also for delivery, especially therapeutic delivery, of the said proteins to subjects.

    摘要翻译： 本发明属于分子生物学领域，涉及重组工程和蛋白质表达。 更具体而言，本发明涉及用于重组表达蛋白质的核酸，其包含衍生自乳杆菌或链球菌的序列并且可用作启动子。 本发明还涉及包含所述核酸和用其转化的宿主细胞的载体。 本发明还涵盖包含所述核酸或载体的宿主细胞用于表达异源或同源蛋白质的用途; 并且还用于将所述蛋白质递送，特别是治疗性递送给受试者。

    LACTOCOCCUS PROMOTERS AND USES THEREOF
    8.
    发明公开
    LACTOCOCCUS PROMOTERS AND USES THEREOF 审中-公开
    LACTOCOCCUS促进剂及其用途

    公开(公告)号：EP3124614A3

    公开(公告)日：2017-04-05

    申请号：EP16177775.0

    申请日：2008-01-14

    申请人： Intrexon Actobiotics NV

    发明人： STEIDLER, Lothar ,  VANDENBROUCKE, Klaas ,  NEIRYNCK, Sabine

    IPC分类号： C12N15/74 ,  A61K38/20 ,  A61K38/19 ,  A61K38/22

    CPC分类号： C12N15/746 ,  A61K38/00 ,  C07K14/5428 ,  C07K14/575 ,  C07K14/605

    摘要： The invention is in the field of molecular biology, and relates to recombinant engineering and protein expression. More in particular, the invention relates to nucleic acids for recombinant expression of proteins comprising sequences derived from Lactococcus and useful as promoters. The invention further relates to vectors comprising the said nucleic acids and host cells transformed therewith. The invention also covers the use of host cells comprising the said nucleic acids or vectors for expressing heterologous or homologous proteins; and also for delivery, especially therapeutic delivery, of the said proteins to subjects.

    摘要翻译： 本发明属于分子生物学领域，涉及重组工程和蛋白质表达。 更特别地，本发明涉及用于重组表达蛋白质的核酸，其包含衍生自乳球菌的序列并且可用作启动子。 本发明还涉及包含所述核酸和用其转化的宿主细胞的载体。 本发明还涵盖包含所述核酸或载体的宿主细胞用于表达异源或同源蛋白质的用途; 并且还用于将所述蛋白质递送，特别是治疗性递送给受试者。

    COMPOSITIONS AND METHODS FOR THE TREATMENT OF TYPE 1 DIABETES
    10.
    发明公开
    COMPOSITIONS AND METHODS FOR THE TREATMENT OF TYPE 1 DIABETES 审中-公开

    公开(公告)号：EP3919065A9

    公开(公告)日：2023-08-02

    申请号：EP21185734.7

    申请日：2017-01-13

    申请人： Intrexon Actobiotics NV

    发明人： Rottiers, Pieter ,  Steidler, Lothar

    IPC分类号： A61K35/744 ,  A61K38/20 ,  A61K39/00 ,  C12N1/20 ,  A61P3/10 ,  A61P37/06 ,  C12N15/09 ,  C12R1/01 ,  C12N1/00

    摘要： Provided herein are compositions and methods for the treatment of type 1 diabetes (T1D) in mammalian subjects. The compositions include lactic acid fermenting bacteria (LAB) expressing an IL-2 gene and a TID-specific self-antigen (e.g., proinsulin (PINS)) gene. Exemplary methods include: orally administering to a mammalian subject, a therapeutically effective amount of the composition. The composition can be administered to the subject mucosally, resulting in delivery of the LAB into the gastrointestinal tract, where the LAB is released. Bioactive polypeptides expressed by the LAB are thus administered via mucosal delivery. The LAB may be selected to deliver a low-dose of IL-2 to the subject. The methods may not require concomitant systemic anti-CD3 antibody treatment. The methods may be suited for subjects possessing residual beta-cell function, e.g., those with recentonset T1D.